EGFR and familial pancreatic carcinoma: Previous studies have established that the employment of EGFR tyrosine-kinase inhibitors (EGFR-TKIs) (such as erlotinib) have achieved encouraging progress in treating patients with pancreatic cancer, unfortunately, after the initial response, many patients would inevitably acquire resistance to erlotinib (9).